ESC pluripotency is maintained by OCT4 (octamer-binding transcription factor 4), NANOG and SOX2 (SRY-box containing protein 2), which form a feedback regulatory circuit positively regulating their own genes and activating genes encoding critical components of pluripotency while repressing genes important for developmental processes 14 . Identification of key regulators of ESC pluripotency provided a foundation for somatic cell reprogramming [15] [16] [17] and is likely to have a critical impact on the use of human ESCs (hESCs) in regenerative medicine. FoxO proteins are mammalian orthologues of DAF-16 (abnormal dauer formation protein 16), an essential protein in the regulation of stress response and ageing in Caenorhabditis elegans 18 . FoxO proteins are primarily phosphorylated and negatively regulated by AKT serine/threonine protein kinase downstream of the PI(3)K (phosphatidylinositol-3-OH kinase) signalling pathway 19, 20 . A number of kinases other than AKT also phosphorylate and regulate FoxO proteins either positively or negatively [21] [22] [23] . In addition to phosphorylation, FoxO proteins are subject to several posttranslational modifications such as acetylation [24] [25] [26] , ubiquitylation 27 , methylation 28 and redox modulation 29 . The combined output of this stringent multilayer regulation determines the subcellular localization of FoxO proteins and ultimately their transcriptional activity 30, 31 . FoxO proteins exert key biological functions (reviewed in ref. 30) that seem overlapping but non-redundant, as evidenced by distinct phenotypes of their respective knockout models 32,33 as well as studies in primary stem and progenitor cells [9] [10] [11] [12] [13] 34 . FoxO proteins are bona fide tumour suppressors, as demonstrated by the phenotype of their conditional deletion in mice 8 , and as such promote cell cycle arrest, induce apoptosis, contribute to DNA damage repair and suppress oxidative stress by modulating genes involved in these processes 30, 31 . To address the potential function of FoxO proteins in human development, we analysed their expression in hESCs. ESC differentiation recapitulates early events of embryogenesis (reviewed in ref. 35), providing a suitable system for biochemical analyses of developmental processes under tightly controlled in vitro conditions. As previously predicted 36 , FOXO1 was the most abundant FOXO at the messenger RNA level in undifferentiated pluripotent H1 hESCs (Fig. 1a and Supplementary Fig. S1 ). Importantly, FOXO1 protein was at least seven times more abundant than FOXO3A and FOXO4 (no FOXO6 mRNA or protein was detectable, Supplementary Fig. S1b-f and data 
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not shown) in these cells. The expression of FOXO1 was markedly downregulated during embryoid body formation and commitment to mesoderm and haematopoietic cells (Fig. 1a) . Interestingly, in undifferentiated self-renewing hESCs, most FOXO1 was nuclear ( Supplementary Fig. S1g) . A similar pattern of FOXO1 distribution was found in a distinct hESC line HES2 ( Supplementary Fig. S2a ) and was highly conserved during mouse ESC (mESC) differentiation ( Supplementary Fig. S2b ), collectively indicating a potential role for FOXO1 in regulating ESC fate. To investigate this, we used two distinct FOXO1-targeting short hairpin RNA (shRNA) sequences and a lentiviral vector to deliver tetracycline-inducible shRNAs to inducibly knockdown FOXO1 in hESCs (H1/FOXO1 shRNA, H1/FOXO1 shRNA II). In these cells, the shRNA is driven by a tet-on hybrid promoter where the polymerase (Pol) III promoter H1 is fused to tetracycline operator sequences such that the shRNA expression requires the addition of doxycycline. For a complete description see the Supplementary Information and Supplementary Fig. S2c -j. In the absence of doxycycline, stable expression of shRNAcontaining lentiviral vectors did not perturb the normal development of experimental or control hESC-derived lines, which maintained pluripotency under appropriate culture conditions, and preserved full embryoid body formation and commitment to mesoderm and haematopoietic cells in vitro (Fig. 1b-e and Supplementary Figs S3 and S4). Three to four days after the addition of doxycycline, FOXO1 transcript was significantly reduced in both H1/FOXO1-shRNA and H1/FOXO1-shRNA-II cells maintained under pluripotency self-renewing conditions (Fig. 1b,c and Supplementary Fig. S4a ). The expression of other FOXO proteins was not significantly altered (Supplementary Figs S4b and S5a,b), nor was their overall nuclear/cytoplasmic distribution ( Supplementary Fig. S5c ), indicating that the observed phenotype was specifically due to FOXO1 downregulation. Importantly, FOXO1-knockdown cells seemed to conserve their rate of growth and survival, as evidenced by the comparable timing of their confluency and the total number of DAPI (4,6-diamidino-2-phenylindole)-positive cells (data not shown).
Next, we assessed the potential effect of FOXO1 knockdown on hESC pluripotency. Specific inhibition of FOXO1 mRNA using two distinct shRNA sequences resulted in >90% depletion of FOXO1 S5f ). Together, these results indicate that FOXO1 has a critical function in the regulation of hESC pluripotency. Interestingly, the effect of FOXO1 knockdown on hESC pluripotency was reversible in that doxycycline withdrawal after 96 h resulted in recovery of FOXO1 expression as well as OCT4, NANOG and SOX2 within a few days ( Fig. 2a and Supplementary Fig. S6 ). These results indicate that FOXO1 tightly controls pluripotency genes. FOXO1 knockdown resulted in the spontaneous differentiation of hESCs maintained under pluripotent self-renewal conditions, as shown by the induction of mesoderm (SCL, also known as TAL1; GATA2; and brachyury, also known as T ) and endoderm lineage markers (AFP, GATA4 and SOX17 ; Fig. 2a and Supplementary Fig. S6a-c ). As none of these genes is known to be directly regulated by FoxO, these results also indicate that FOXO1 regulation of pluripotency is due in part to its participation in suppressing the mesoderm and endoderm lineage commitment. In this context, FOXO1 knockdown did not impact the expression of markers of ectoderm specification NES, TUBB3 and GFAP (data not shown).
In agreement with a critical function of FOXO1 in the regulation of hESC pluripotency, lentiviral-mediated ectopic FOXO1 expression induced a significant upregulation of OCT4, NANOG and SOX2 in two different hESC lines (Fig. 2b and Supplementary Fig. S6d ). These effects were specific to FOXO1, because ectopic expression of FOXO3A in these same two hESC lines did not significantly alter the expression of pluripotency genes ( Fig. 2b and Supplementary  Fig. S6d ). Of note, overexpression of FOXO1 in hESCs also resulted in upregulation of KLF4 and REST, genes associated with mESC pluripotency 37, 38 (Fig. 2b) . Targeting FOXO1 in hESCs undergoing few passages in self-renewing conditions (Fig. 2c-e and Supplementary Fig. S7a , top) resulted in a morphological transition towards an epithelial flattened appearance. These morphological changes were accompanied by a nearly complete loss of alkaline phosphatase activity (Fig. 2c) , loss of cell surface markers of pluripotency ( Fig. 2d and Supplementary Fig. S7a ) and loss of transcripts for OCT4, NANOG and SOX2 ( Fig. 2e and Supplementary  Fig. S7b ), all indicating loss of pluripotency in FOXO1-knockdown cells after few passages. Importantly, these alterations were concomitant with full acquisition of differentiation markers ( Fig. 2e and Supplementary  Fig. S7c,d ). In contrast to its short-term impact (Fig. 2a) , the effect of FOXO1 knockdown on pluripotency did not seem to be reversible after few passages, indicating that FOXO1 is critical for the maintenance of pluripotency in hESCs over time ( Supplementary Fig. S7e ).
Signalling pathways regulating ESC fate differ between mESCs and hESCs, whereas transcriptional programs of pluripotency are relatively conserved 39, 40 . Importantly, as in hESCs, we found Foxo1 (mouse orthologue of FOXO1) to be critical for the regulation of pluripotency and differentiation of mESCs (Fig. 3) , as determined by loss of alkaline phosphatase activity (Fig. 3a) , suppression of pluripotency gene expression (Fig. 3b, top) and upregulation of certain developmental genes, such as the mesoderm specific brachyury (T ; Fig. 3b, bottom) . However, in contrast to hESCs, Foxo1 knockdown resulted in the upregulation of the Cdx2 (caudal type homeobox 2) trophoblastic marker in mESCs, as would have been predicted from OCT4 downregulation 41 . This result probably reflects differences in responses to OCT4 downmodulation in mESCs versus hESCs that represent discrete pluripotency states developmentally at distinct stages 42 . Interestingly, in mESCs, although Foxo3 knockdown also resulted in loss of pluripotency (Fig. 3c, top) , it did not lead to modulations of brachyury expression as seen with Foxo1 knockdown (Fig. 3c, bottom) , indicating a potential function for Foxo3 in upregulation of brachyury gene expression during mesoderm induction.
To further confirm the specificity of loss of FoxO1 on pluripotency, we rescued the observed phenotype by overexpression of a resistant form of the targeted FoxO1 using two different strategies in both hESCs (Fig. 3d) and mESCs (Fig. 3e and data not shown) . These findings validated unambiguously our results implicating FoxO1 in the regulation of pluripotency in ESCs.
hESCs form teratoma-like masses when introduced into immunodeficient mice 43 . This generally accepted approach demonstrates the developmental potential of pluripotent hESCs in vivo. We reasoned that if FOXO1 is critical for hESC pluripotency, loss of its activity Supplementary Fig. S12 ).
should prevent hESCs from forming teratomas in vivo. Whereas almost all immunocompromised severe combined immunodeficient (SCID)-Beige mice injected with control cells formed well-encapsulated cystic tumours that contained elements of all three embryonic germ layers, only two of nine mice injected with doxycycline-induced H1/FOXO1 shRNA formed tumours, all of which were relatively small ( Supplementary Fig. S8a-m) .
To investigate the mechanism of FOXO1 control of pluripotency, we investigated whether FOXO1 regulates hESC cycling, apoptosis or redox status. FOXO1 knockdown did not significantly modulate hESC proliferation (Fig. 4a and Supplementary Fig. S8n ), or apoptosis ( Supplementary Fig. S8o ). In addition, it did not alter the expression of anti-oxidant enzymes or stress genes that accompany oxidative stress particularly in stem cells 9, 10 (Fig. 4b) . In agreement with these results, reactive oxygen species (ROS) levels were not significantly increased in FOXO1-knockdown hESCs (Supplementary Fig. S8p) . Furthermore, the anti-oxidant N -acetyl-cysteine (NAC) treatment did not impact pluripotency genes in these cells (Fig. 4c) , altogether strongly arguing against redox modulation in mediating the effect of FOXO1 on pluripotency.
These results led us to investigate whether FOXO1 directly regulates pluripotency gene expression. Using rVista tools, multi-LAGAN alignment and the TRANSFAC database, we analysed 5-kb regions upstream of pluripotency genes. These analyses identified highly conserved sequences containing putative FoxO binding sites 44 within the regulatory regions of OCT4 (O1, O2) and SOX2 (S1, S2, S3) genes (S1 and S3 each containing two clusters each) but not those of the NANOG gene (Fig. 5a) .
In pluripotent self-renewing hESCs, endogenous FOXO1 bound specifically to sequences within regulatory regions of OCT4 (O2) and SOX2 (S1, S3) genes, as revealed by chromatin immunoprecipitation (ChIP; Fig. 5b and Supplementary Fig. S9a,b) . In these experiments the p27 KIP1 promoter, a known FOXO target, served as a positive control, whereas a conserved upstream region of human OCT4 (NEG Seq O) and human SOX2 (NEG Seq S) lacking FOXO-binding sequences served as negative controls. Importantly, FOXO1 binding to these sites was significantly reduced in doxycycline-treated cells when compared with controls (Fig. 5c) , further validating the specificity of FOXO1 binding. These in vivo findings were corroborated by in vitro gel mobility shift assays using nuclear extracts of HEK293T cells ectopically expressing FOXO1 (Supplementary Figs. S9c,d ). In agreement with these results, reporter assays showed that FOXO1 activates OCT4 and SOX2 transcription through regulation of O2 in OCT4, and the S1 and S3 regions in SOX2 (Fig. 5d and Supplementary Fig. S10a-c) . These experiments also revealed that FOXO3A binds to the O2 sequence of OCT4 in hESCs and activates to some extent OCT4 luciferase reporter in HEK293T cells (Fig. 5b,d ). To further evaluate this, we examined the activation of the full-length (3 kb) human OCT4 promoter by overexpressed FOXO proteins in hESCs. As shown in Fig. 5e , ectopically expressed FOXO1 highly activates (four times more than FOXO3A) human OCT4 in hESCs. Importantly, mutation of the O2 sequence abolishes the activation, indicating that O2 is the principal mediator of FOXO1 induction of OCT4 in hESCs.
In contrast to FOXO1, and consistent with overexpression studies in hESCs ( Fig. 2b and Supplementary Fig. S6d ), FOXO3A did not bind to SOX2 regulatory regions in vivo, nor did it have any impact on SOX2 transcription (Fig. 5b,d and Supplementary Fig. S10b ), despite binding to the SOX2 promoter in gel mobility shift assays in vitro (Supplementary Fig. S10e) .
The differential impact of FOXO1 versus FOXO3A on pluripotency genes may be explained by the differential regulation of FOXO proteins, and specifically their nuclear localization, in hESCs (see Supplementary  Figs S1g and S5c) . Indeed, the function of FoxO proteins is determined by the integrated balance of competing stimuli 30, 31 . Notable among negative regulators of FOXO proteins is AKT, which is critical for ESC self-renewal 45, 46 . AKT-dependent phosphorylation of FOXO proteins triggers their rapid nuclear export by multiple means to ensure the inhibition of their transcriptional activity 30, 31 . As anticipated, in self-renewing hESCs the PI(3)K/AKT signalling pathway is activated in response to basic fibroblast growth factor (bFGF) stimulation resulting in AKT phosphorylation of FOXO1 (Fig. 5f, lanes 2-5) . Interestingly, FOXO1 (but not FOXO3A) is mostly nuclear despite abundant pAKT in hESCs cultured in bFGF (Fig. 5f, lane 1, Fig. 5g, top and Supplementary Fig. S11 ).
Inhibition of AKT by the PI(3)K inhibitor LY294002 leads to FOXO1 dephosphorylation and increased nuclear FOXO1 intensity ( Fig. 5f,  lane5; Fig. 5g ). These results indicate that in hESCs, FOXO1 is nuclear and transcriptionally active despite its phosphorylation by AKT, presumably because its inhibition by pAKT is overriden by other signalling pathways 28 . These findings are reminiscent of regulation of Foxo3 in adult stem cells 10, 47 and are consistent with the notion that the output of competing signalling pathways (and not AKT alone) ultimately determines the nuclear localization and activity of FOXO proteins 30, 31 . The present study demonstrates an essential function for FOXO1 in the regulation of hESC fate. Thus, the longevity FoxO proteins emerge as critical non-redundant regulators of both somatic and embryonic stem cell activity. Specifically, Foxo3 is essential for the maintenance of haematopoietic, neural and leukaemic stem cells [9] [10] [11] [12] [13] , whereas FOXO1 is critical for regulating hESC pluripotency. Similarly to certain other pluripotency gene-deleted mice such as Sox2 refs 7,48,49) , Foxo1 −/− mice do not exhibit an early (pre-gastrulation) developmental defect 33 . This may be due to the regulation of pluripotency by both Foxo1 and Foxo3 in mESCs in contrast to hESCs (mESCs being at an earlier developmental stage than hESCs) 42 , indicating that perhaps during early stages of mouse development Foxo1 and Foxo3 are redundant in vivo, as supported by our findings in mESCs (Fig. 3) . Alternatively, lack of early lethality of Foxo1 −/− mice may be due to species-specific differences or, as in the case of Sox2 −/− (ref. 7) , to the potential presence of long-lived maternal Foxo1 protein at the early stages of Foxo1 −/− embryonic development. Given OCT4 binding to FOXO1 promoter in hESCs 14 , these findings indicate that FOXO1 is a component of the circuitry of hESC pluripotency and support the notion that activation of FOXO1 may be used for improving somatic cell reprogramming [15] [16] [17] .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology Technologies) . hESC differentiation and haematopoietic colony-forming assays were carried out as previously described 50 . mESC maintenance and differentiation were carried out as previously described 46 . Cells were stained with anti-TRA-1-81 (Santa Cruz), anti-KDR-PE (R&D Systems), anti-CD34-PE-cy7 (BD Pharmingen), anti-PECAM-1 (CD31)-FITC (BD Pharmingen) and/or anti-CD117-APC (Invitrogen) and analysed with a fluorescence-activated cell sorting (FACS) LSRII flow cytometer (Becton Dickinson).
Plasmids, generation of H1TetR cells, lentiviral production, ESC transduction and PCR reactions. H1 hESCs (2 × 10 6 ) were transfected with 5 µg of FspI-linearized tetracycline repressor protein (TetR)-expressing plasmid pcDNA6/TR (Invitrogen) using nucleofection (Amaxa kit VPH-1001 & Nucleofector). Blasticidin-S-resistant (5 µg ml −1 , Invitrogen) hESC colonies were picked two weeks later, expanded and maintained in the presence of 10 µg ml −1 blasticidin S. One of positive colonies was used in subsequent experiments.
All shRNAs (Supplementary Table S1 ) used in hESCs were cloned into EcoRI/XhoI sites of the pL4-H1/TetO4 lentiviral vector. FOXO1 shRNA III targets the 3 untranslated region of the FOXO1 mRNA. shRNAs used in mESCs were inserted into the lentivirus-based pLKO.bsd vector. FOXO1 and FOXO3A complementary DNAs were cloned into the HpaI site of the pLEIGW vector. The 3-kb human OCT4 promoter from phOCT4-Luc (plasmid # 17221, Addgene) 16 , amplified by PCR (see Supplementary Table S1 ), and the regulatory regions containing putative FOXO-binding sites of human OCT4 or SOX2 were inserted between KpnI and BglII sites of the pGL3 vector containing a TATA box 51 . shRNAresistant Foxo1 (Foxo1-m4), generated by site-directed mutagenesis without altering the amino acid sequence, was inserted into the pSIN-EF1 α-IRES-Puro lentiviral vector. Lentiviral vectors were packaged by co-transfection of pLP1, pLP2 and pLPVSVG plasmids (all from Invitrogen) into HEK293T cells, concentrated and stored at Sequence alignment and identification of FOXO-binding sites in OCT4 and SOX2 regulatory regions. To identify the putative FOXO-binding sites in OCT4 and SOX2 regulatory regions, the most recent annotated versions of the 5-kb genomic sequences upstream of the transcription start site of the OCT4 and SOX2 locus in mouse, rat and human were obtained from the ENSEMBL Genome Browser (http://www.ensembl.org). The three-way alignment was created using the Multi-LAGAN tool (http://genome.lbl.gov/vista/phylovista/index.shtml). The rVista tool (http://rvista.dcode.org) was run to identify putative FoxO binding sites. Conserved binding sites are defined in rVista as sequence fragments conserved between at least two species at the level of over 80% over a 24-base-pair window. For comparison, visualization of the alignment and FOXO-binding site searches within the alignment were repeated using the TRANSFAC database (http://www. generegulation.com/pub/databases.html).
Reporter gene assay. HEK293T (1.5 × 10 5 cells per well) were co-transfected with 0.5 µg pcDNA3-FOXO1, pcDNA3-FOXO3A or an empty control vector and 0.5 µg of the Firefly luciferase reporter gene along with 50 ng pRL-TK (Promega). hESCs (1 × 10 6 H1 cells) were co-transfected with 2.5 µg pLEIGW-FOXO1, pLEIGW-FOXO3A or pLEIGW empty vector and 2.5 µg of the luciferase reporter vector along with 250 ng pRL-TK (Promega) using nucleofection. Firefly luciferase activity was normalized to the corresponding Renilla luciferase activity.
Measurement of intracellular ROS levels. ROS levels were measured as previously described 10, 13, 34 . hESCs (5 × 10 5 ) were probed with 2,3,4,5,6-pentafluorodihydrotetramethylfosamine (RedoxSensor Red CC-1; Molecular Probes-Invitrogen, 3 µM), and hESCs incubated with H 2 O 2 (200 µM) were used as positive controls.
Electrophoretic mobility shift assay. Nuclear extracts of HEK293T cells were isolated in two steps using hypotonic buffer (20 mM HEPES, 10 Mm KCl, 1 mM MgCl 2 , 0.5 mM dithiothreitol, 0.1% Triton X-100 and 20% glycerol) containing protease inhibitors (Roche) and nuclear extraction buffer (hypotonic buffer with 420 mM NaCl) and stored at −80 • C. The 2× DNA-protein binding reaction buffer was composed of 100 mM KCl, 20 mM MgCl 2 , 0.1 mM dithiothreitol, 1% NP-40 and 5% glycerol in 20 mM Tris-HCl at pH 7.5, supplemented with 0.1 µg ml −1 polydeoxyinosinic-deoxycytidylic acid. Total nuclear extracts (5 µg) were used in each binding reaction in a total volume of 20 µl at room temperature. A total of 100 ng of each probe (S1, S3, O2 wild type and mutant, and insulin response sequence as a positive control) 19 was labelled with [γ -32 P]ATP (PerkinElmer) using the T4 Polynucleotide Kinase. In competition experiments, 200 molar excess of unlabelled probe was added to the binding reaction 15 min before the 32 P-labelled probe. For supershift experiments, nuclear extracts were pre-incubated with 2 µg of anti-FOXO1 (N-18) or anti-HA antibodies (Santa Cruz Biotechnology) for 45 min at 4 • C.
Cell proliferation and apoptosis. BrdU (5-bromodeoxyuridine) labelling and annexin V-binding assays were carried out as previously described 10, 13 . Ki-67 staining for flow cytometry was carried out according to the manufacturer's recommendations.
Histochemistry and immunocytochemistry staining. Alkaline phosphatase activity was detected using Alkaline Phosphatase Substrate kit I (Vector Laboratories) following the manufacturer's protocol.
Cells were fixed with 4% paraformaldehyde, then permeablized with 0.3% Triton X-100 for 30 min followed by washing and blocking with 4% goat serum in PBS. secondary antibodies (Invitrogen) were used at 1:500 dilution (1:100 for brachyury staining). Double immunostaining was carried out using anti-FOXO1 (N-18; Santa Cruz) and anti phospho-AKT (Ser 473; Cell Signalling) at 1:50 and 1:25 dilution, respectively. After washing three times, slides were mounted using Vectashield with DAPI (Vector Laboratories) and visualized by a Leica DMRA2 fluorescence microscope (Leica).
Southern blot analysis. Genomic DNA was isolated using a DNeasy Tissue kit (QIAGEN), digested with EcoRI and KpnI, separated by 1% agarose gel electrophoresis and transferred to a nylon membrane (Amersham Bioscience) in 10 × SSC (1.5 M NaCl and 0.15 M sodium citrate) overnight. PCR-amplified TetR and enhanced fluorescent green protein (eGFP) gene fragments were used as probes for hybridization. The TetR probe detects a 1.5-kb band and the eGFP probe a 1.7-kb band.
Teratoma formation. Doxycycline-treated or non-treated hESCs (1 × 10 6 ) were resuspended in 20 µl hESC media and injected under the kidney capsule of four-week-old male SCID-Beige mice. Four to eight weeks later, tumours (>5 mm in diameter) were surgically removed, fixed in 4% paraformaldehyde overnight and embedded in paraffin. Sections were stained with haematoxylin and eosin.
Statistical analysis. Data represent mean ± s.e.m. of the number (n) of independent experiments unless indicated otherwise. Statistical significance has been calculated by a two-tailed Student t -test between the indicated groups.
